Attention: The following specifications apply to the USA and Europe. All other countries, click here. |
|
| |
Speed-up your discovery.
- Superior hybridization characteristics
- Enhanced biostability
|
|
LNA Bibliography
|
What is LNA?
LNA is a novel type of nucleic acid analog that contains a
2'-O, 4'-C methylene
bridge. This bridge restricts the flexibility of the ribofuranose ring and locks the
structure into a rigid C3-endo conformation, conferring enhanced hybridization performance
and exceptional biostability.
|
LNA® oligos are innovative oligonucleotides that contain Locked Nucleic Acids™
(LNA) to provide superior hybridization characteristics and enhanced
biostability compared to conventional DNA oligonucleotides.
LNA-containing oligos are provided as follows:
- Deprotected and desalted
- Purified by PAGE, RPC or RP-HPLC upon request
- Delivered in solution in deionized water or dried down
- Systematic QC by MALDI-TOF mass spectrometry analysis and - depending
upon the nature of the oligonucleotide requested - by RP-HPLC or IE-HPLC
- Please contact Sigma-Genosys for expected TATs
LNA oligos are composed of either 100% Locked Nucleic Acid (LNA) bases or a mixture of
LNA and DNA bases. However, only oligonucleotides that are between 7 and 15 mers in length
can be made up of 100% LNA. Oligos heavy in LNA content may exhibit problematic
self-complementarity. Therefore, for oligonucleotides longer than 15 mers, we recommend
decreasing the LNA content as the oligonucleotide increases in length, as follows:
Length
of LNA oligo |
7 - 15 mers
|
16 - 25 mers
|
26 - 40 mers
|
41 - 60 mers
|
Percentage
of LNA |
up to 100%
|
up to 60%
|
up to 40%
|
up to 20%
|
Please contact Sigma-Genosys design specialists to discuss application-specific LNA
design.
LNA oligos are available at our standard synthesis scales (0.05, 0.2, 1 µmole). LNA
bases may also be incorporated into our Real-time qPCR
probes. Consult with your local office for guaranteed yield and delivery times.
LNA oligonucleotides can be designed to enhance a wide variety of genomic applications
and technologies that rely upon the use of oligonucleotides:
- Hybridization probes for the detection of nucleic acids and genotyping
- Padlock probes, modified Taqman™ probes and probes for in situ
hybridization
- Capture probes for target enrichment, sample preparation and affinity
chromatography
- Allele-specific PCR1
- Antisense oligonucleotide technology
- Oligonucleotides
for therapeutic or diagnostic applications, such as, aptamers, ribozymes, decoy
oligonucleotides and siRNA
- PCR-based applications
In most respects, LNA oligonucleotides can be used in the same manner as DNA
oligonucleotides: it is soluble in aqueous buffers, can be ethanol precipitated, dried and
resuspended, and analyzed by gel electrophoresis, HPLC and MALDI-TOF.
Specifications of LNA Oligos
|
Quality control
|
Every oligo is quality checked by MALDI-TOF mass spectrometry, electrospray ionization
mass spectrometry (ESI-MS), capillary electrophoresis (CE), and/or polyacrylamide gel
electrophoresis (PAGE).
|
|
Purification
|
Fully deprotected and desalted
Purified by PAGE, RPC or RP-HPLC upon request
|
|
Length
|
7 to 15 mers: up to 100% LNA base content
7 to 60 mers: LNA / DNA mix
|
|
Bases
|
LNA (+A, +C, +G or +T) (+ denotes the LNA
base)
|
|
Backbone
|
Phosphodiester and/or phosphorothioate bonds
|
|
Form
|
Dried format, 2 mL screw cap tubes. Concentration normalization available upon
request.
|
|
Storage and stability
|
See information on our oligos: storage
recommendations
|
|
Shipment
|
Shipped by express delivery, in individual tubes
|
|
Documentation
|
All Oligos are delivered with Quality Assurance document including yields, Tm (melting
temperature), MW, and µg/OD. An extra vial label for your records accompanies oligos
in tubes.
|
|
Services available upon request
|
• Aliquoting
• Adjusted concentration
• Design support
• Additional services may increase turn-around time
• Plate services
|
|
Pricing
|
Please contact your local Sigma-Genosys representative
|
1 PCR (Polymerase Chain Reaction) is patented by Hoffman La Roche
Ltd.
|
